License and Collaboration Agreements - Summary of Accounts Receivables (Detail) - USD ($) $ in Thousands |
Jun. 30, 2026 |
Dec. 31, 2025 |
|---|---|---|
| Current accounts receivable: | ||
| Other unbilled | $ 23 | $ 19 |
| Current accounts receivable | 106,754 | 26,379 |
| Non-current accounts receivable: | ||
| Other unbilled | 435 | 454 |
| Non-current accounts receivable | 435 | 2,312 |
| Total accounts receivable | 107,189 | 28,691 |
| AbbVie for development milestone [Member] | ||
| Current accounts receivable: | ||
| Billed to customers | 100,000 | |
| Other [Member] | ||
| Current accounts receivable: | ||
| Billed to customers | 385 | 557 |
| Novartis Royalties [Member] | ||
| Current accounts receivable: | ||
| Unbilled | 4,124 | 23,806 |
| Nippon Shinyaku Services [Member] | ||
| Current accounts receivable: | ||
| Unbilled | $ 2,222 | 1,997 |
| Non-current accounts receivable: | ||
| Unbilled | $ 1,858 |